Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImaging Bio Regulatory News (IBAI)

Share Price Information for Imaging Bio (IBAI)

Share Price is delayed by 15 minutes
Get Live Data
0.70    0.00 (0.00%)
Bid:
0.60
Ask:
0.80
Spread: 0.20 (33.333%)
Market Cap: £1.73m
IBAI Live PriceLast checked at - London Stock Exchange

Intraday Imaging Bio Share Chart

Director/PDMR Dealing

9 Jul 2025 17:14

RNS Number : 4320Q
Imaging Biometrics Limited
09 July 2025
 

Imaging Biometrics Limited

("IB" or the "Company")

 

PDMR dealing

 

Imaging Biometrics Limited, a leader in quantitative imaging solutions and novel therapies for CNS malignancies, announces that it has been notified of the following transactions in ordinary shares in the Company undertaken by directors/persons discharging managerial responsibility (PDMR).

 

The notification below is made in accordance with Article 19(3) of the Market Abuse Regulation.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Michael Schmainda

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor

 

a)

 

Name

 

 

Imaging Biometrics, Ltd

b)

 

LEI

 

 

213800SPW48XRJS2QH57

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each in Imaging Biometrics, Ltd

Identification code

JE00BD4H0R42

b)

 

Nature of the transaction

 

 

Purchase of shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

0.7 pence

200,000 Ordinary Shares

d)

 

Aggregated information

- Aggregated volume

200,000

- Price

£1400

e)

 

Date of the transaction

 

 

09/07/2025

f)

 

Place of the transaction

 

 

London Stock Exchange (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAKXNEFASEFA
Date   Source Headline
9th Jun 20267:00 amRNSPublication of Phase 1 Clinical Trial
5th Jun 20267:00 amRNSCommercialisation, Phase II Results & Revenue Path
3rd Jun 202611:30 amRNSResult of AGM
3rd Jun 20267:00 amRNSAGM Statement and Business Update
13th May 20267:00 amRNSAMENDEMENT TO NOTICE OF ANNUAL GENERAL MEETING
12th May 20262:24 pmRNSNOTICE OF ANNUAL GENERAL MEETING
8th May 20267:00 amRNSKIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA
30th Apr 20264:18 pmRNSAnnual Report for the Year Ended 31 December 2025
19th Feb 202610:48 amRNSBoard Appointment
11th Feb 20267:00 amRNSUpdate and IB Nimble Webinar – 27 February 2026
16th Jan 20267:00 amRNSIBAI: Strategic Direction Fueling Organic Growth
10th Dec 20259:43 amRNSExpansion Global Distribution Agreement with GE
26th Nov 20252:50 pmRNSRelease of Next-Generation IB Clinic
24th Nov 20259:56 amRNSBoard Changes
13th Nov 202511:24 amRNSFractional Tumor Burden Mapping Enhances GBM Trial
10th Nov 20253:14 pmRNSIB Announces Completion of Phase 1 Trial of GaM
16th Oct 20257:00 amRNSFurther Re: Purchase of interest in Kirkstall Ltd
14th Oct 202512:15 pmRNSPurchase of Kirkstall and CLN - Correction
14th Oct 20257:00 amRNSPurchase of Kirkstall and CLN with Truetide plc
3rd Oct 202512:16 pmRNSVivan Therapeutics and IB Announce Partnership
16th Sep 20253:49 pmRNSIB Enters Agreement with MedImageMetric
13th Aug 202511:48 amRNSHalf-year Report
7th Aug 202511:22 amRNSGrant of Share Options
21st Jul 20257:00 amRNSIB Announces Soft Close to Phase 1 Trial
9th Jul 20255:14 pmRNSDirector/PDMR Dealing
12th Jun 202510:30 amRNSIB Provides Update on BTD Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.